Results 281 to 290 of about 12,310,007 (328)

Correction: Pica practices, anemia, and oral health outcomes: a systematic review. [PDF]

BMC Oral Health
Abu BAZ, Morrissey A, Wu Y, Castillo DA, Becker R, Wu T, Fiscella K, Gill S, Xiao J.   +8 more
europepmc   +1 more source

The critical role of DNA damage‐inducible transcript 4 (DDIT4) in stemness character of leukemia cells and leukemia initiation

Molecular Oncology, EarlyView.
Stemness properties, including quiescence, self‐renewal, and chemoresistance, are closely associated with leukemia relapse. Here, we demonstrate that DNA damage‐inducible transcript 4 (DDIT4) is induced in the hypoxic bone marrow niche and is essential for maintaining the stemness of AML1‐ETO9a leukemia cells.
Yishuang Li, Zhijie Cao, Haiyan Xing, Zhenya Xue, Wenbing Liu, Jiayuan Chen, Yihan Mei, Runxia Gu, Hui Wei, Shaowei Qiu, Min Wang, Qing Rao, Jianxiang Wang   +12 more
wiley   +1 more source

Corrigendum to "Leveraging large language models to predict antibody biological activity against influenza A hemagglutinin" [Comput Struct Biotechnol J 27 (2025) 1286-1295]. [PDF]

Comput Struct Biotechnol J
Barkan E, Siddiqui I, Cheng KJ, Golts A, Shoshan Y, Weber JK, Mota YC, Ozery-Flato M, Sautto GA.   +8 more
europepmc   +1 more source

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations

Molecular Oncology, EarlyView.
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi, Mirjam Balbisi, Simon Sugár, Lóránd Váncza, Eszter Regős, Ilona Kovalszky, Ibolya Laczó, Tünde Harkó, Gábor Kecskeméti, Zoltán Szabó, Judit Moldvay, László Drahos, Lilla Turiák   +12 more
wiley   +1 more source

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

Molecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh, Liping Su, Suet Lin Chia, Xiaohe Tian, Haslina Ahmad, Martin R. Gill   +5 more
wiley   +1 more source

Author Correction: Mapping multimodal phenotypes to perturbations in cells and tissue with CRISPRmap. [PDF]

Nat Biotechnol
Gu J, Iyer A, Wesley B, Taglialatela A, Leuzzi G, Hangai S, Decker A, Gu R, Klickstein N, Shuai Y, Jankovic K, Parker-Burns L, Jin Y, Zhang JY, Hong J, Niu X, Costa JA, Pezet MG, Chou J, Chen C', Paiva M, Snoeck HW, Landau DA, Azizi E, Chan EM, Ciccia A, Gaublomme JT.   +26 more
europepmc   +1 more source

Pericytes change function depending on glioblastoma vicinity: emphasis on immune regulation

Molecular Oncology, EarlyView.
Pericytes alter their transcriptome depending on their proximity to the tumor core. In the tumor core, pericytes display a more active state with higher communication strength but with lower immune activation potential and a shift toward extracellular matrix production.
Carolina Buizza, Robert Carlsson, Coralie Gamper, Gayatri Chitale, Johan Bengzon, Gesine Paul   +5 more
wiley   +1 more source

Author Correction: Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration. [PDF]

Nat Aging
Saloner R, Staffaroni AM, Dammer EB, Johnson ECB, Paolillo EW, Wise A, Heuer HW, Forsberg LK, Lario-Lago A, Webb JD, Vogel JW, Santillo AF, Hansson O, Kramer JH, Miller BL, Li J, Loureiro J, Sivasankaran R, Worringer KA, Seyfried NT, Yokoyama JS, Spina S, Grinberg LT, Seeley WW, VandeVrede L, Ljubenkov PA, Bayram E, Bozoki A, Brushaber D, Considine CM, Day GS, Dickerson BC, Domoto-Reilly K, Faber K, Galasko DR, Gendron T, Geschwind DH, Ghoshal N, Graff-Radford N, Hales CM, Honig LS, Hsiung GR, Huey ED, Kornak J, Kremers W, Lapid MI, Lee SE, Litvan I, McMillan CT, Mendez MF, Miyagawa T, Pantelyat A, Pascual B, Masdeu J, Paulson HL, Petrucelli L, Pressman P, Rademakers R, Ramos EM, Rascovsky K, Roberson ED, Savica R, Snyder A, Sullivan AC, Tartaglia MC, Vandebergh M, Boeve BF, Rosen HJ, Rojas JC, Boxer AL, Casaletto KB, ALLFTD Consortium.   +71 more
europepmc   +1 more source

RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR‐targeted therapies

Molecular Oncology, EarlyView.
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha, Joana Pinheiro, Rui F. Marques, Patrícia Fontão, Diana Cardoso‐Carneiro, Adriana Mendes, Izabela N. F. Gomes, Ana Carolina Laus, Renato J. da Silva‐Oliveira, Rui Manuel Reis, Olga Martinho   +10 more
wiley   +1 more source

Integrating hepatology with addiction care for inpatients with alcohol use disorder reduces future liver-related events. [PDF]

Hepatol Commun
George P, Marshall C, Zhang W, Goodman R, Butler M, Patel SJ, Mitchell M, Schaefer E, Luther J.   +8 more
europepmc   +1 more source